Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-25-014198·Inhibikase Therapeutics, Inc.
Schedule 13G ownership disclosure
Inhibikase Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 45719W205
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Nantahala Capital Management, LLC
Shares: 5,298,624.00 · Class: 7.54%
- Wilmot B. Harkey
Shares: 5,298,624.00 · Class: 7.54%
- Daniel Mack
Shares: 5,298,624.00 · Class: 7.54%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-014198
- Form type
- SCHEDULE 13G
- Filer
- Inhibikase Therapeutics, Inc.
- CIK
- CIK 1750149
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership